Cancer Stem Cells and Their Possible Implications in Cervical Cancer: A Short Review.
EMT
cancer stem cells
cervical cancer
delivery systems
drug resistance
epigenetic
quiescence
radio-resistance
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 May 2022
05 May 2022
Historique:
received:
06
04
2022
revised:
01
05
2022
accepted:
04
05
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Cervical cancer (CC) is the fourth most common type of gynecological malignancy affecting females worldwide. Most CC cases are linked to infection with high-risk human papillomaviruses (HPV). There has been a significant decrease in the incidence and death rate of CC due to effective cervical Pap smear screening and administration of vaccines. However, this is not equally available throughout different societies. The prognosis of patients with advanced or recurrent CC is particularly poor, with a one-year relative survival rate of a maximum of 20%. Increasing evidence suggests that cancer stem cells (CSCs) may play an important role in CC tumorigenesis, metastasis, relapse, and chemo/radio-resistance, thus representing potential targets for a better therapeutic outcome. CSCs are a small subpopulation of tumor cells with self-renewing ability, which can differentiate into heterogeneous tumor cell types, thus creating a progeny of cells constituting the bulk of tumors. Since cervical CSCs (CCSC) are difficult to identify, this has led to the search for different markers (e.g., ABCG2,
Identifiants
pubmed: 35563557
pii: ijms23095167
doi: 10.3390/ijms23095167
pmc: PMC9106065
pii:
doi:
Substances chimiques
MSI1 protein, human
0
Nerve Tissue Proteins
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Cooperation in Science and Technology
ID : CA18117
Références
Oncotarget. 2016 May 31;7(22):31943-54
pubmed: 27008711
Drug Des Devel Ther. 2016 Jun 07;10:1885-95
pubmed: 27354763
Expert Opin Drug Metab Toxicol. 2019 Aug;15(8):671-682
pubmed: 31340683
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
PLoS One. 2014 Jan 28;9(1):e87092
pubmed: 24489842
Free Radic Biol Med. 2013 Mar;56:89-101
pubmed: 23195683
World J Stem Cells. 2020 Nov 26;12(11):1307-1326
pubmed: 33312400
Eur Rev Med Pharmacol Sci. 2016 May;20(9):1745-54
pubmed: 27212166
Cancer Treat Rev. 2016 Sep;49:25-36
pubmed: 27434881
Oncogenesis. 2016 Feb 15;5:e197
pubmed: 26878391
J Int Med Res. 2014 Aug;42(4):1038-42
pubmed: 24827824
Front Genet. 2021 Dec 01;12:747090
pubmed: 34925445
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2810-2820
pubmed: 31284775
Signal Transduct Target Ther. 2020 Jul 29;5(1):137
pubmed: 32728057
Oncogene. 2014 Sep 4;33(36):4451-63
pubmed: 24096485
Cell Stem Cell. 2014 Mar 6;14(3):306-21
pubmed: 24607405
Cell Syst. 2017 Nov 22;5(5):445-459.e5
pubmed: 29102360
J Cell Physiol. 2020 Jun;235(6):5050-5058
pubmed: 31912897
Oncotarget. 2017 May 30;8(22):35482-35483
pubmed: 28415657
Clin Epigenetics. 2021 Aug 27;13(1):166
pubmed: 34452630
Cells. 2021 Apr 30;10(5):
pubmed: 33946480
Cancer Lett. 2021 Jan 28;497:243-254
pubmed: 33122098
Pharmacol Ther. 2016 Apr;160:145-58
pubmed: 26899500
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):161-168
pubmed: 30213750
J Hematol Oncol. 2020 May 26;13(1):60
pubmed: 32456660
Int J Nanomedicine. 2018 Oct 04;13:6049-6058
pubmed: 30323592
Curr Oncol Rep. 2017 Aug 12;19(10):66
pubmed: 28803390
Nat Rev Cancer. 2018 Nov;18(11):669-680
pubmed: 30228301
Int J Oncol. 2017 Mar;50(3):853-862
pubmed: 28112371
Signal Transduct Target Ther. 2021 Feb 15;6(1):62
pubmed: 33589595
Int J Nanomedicine. 2020 Feb 26;15:1283-1295
pubmed: 32161458
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Asian Pac J Cancer Prev. 2012;13(4):1325-31
pubmed: 22799327
Crit Rev Oncol Hematol. 2021 Jan;157:103178
pubmed: 33279812
PLoS One. 2013 Jun 06;8(6):e65158
pubmed: 23762304
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10516-21
pubmed: 22689991
BMC Cancer. 2020 Sep 17;20(1):891
pubmed: 32942996
Br J Radiol. 2019 Jan;92(1093):20170955
pubmed: 29513032
Oncotarget. 2014 Aug 30;5(16):7027-39
pubmed: 25216521
Mol Vis. 2005 Sep 12;11:729-37
pubmed: 16179903
Cancers (Basel). 2020 Apr 13;12(4):
pubmed: 32295073
Phytomedicine. 2011 Jan 15;18(2-3):199-204
pubmed: 20739156
Nat Rev Clin Oncol. 2015 Jul;12(7):378-80
pubmed: 26031784
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
MAbs. 2009 Jan-Feb;1(1):12-25
pubmed: 20046569
Int J Mol Sci. 2021 Apr 07;22(8):
pubmed: 33917022
Cancer Res. 1996 Oct 1;56(19):4509-15
pubmed: 8813149
Radiother Oncol. 1993 Jan;26(1):45-50
pubmed: 8438086
Br J Radiol. 1978 Nov;51(611):879-87
pubmed: 361144
Cytotechnology. 2012 Aug;64(4):477-84
pubmed: 22431223
J Cell Physiol. 2019 Jun;234(6):8381-8395
pubmed: 30417375
RNA. 2013 Jan;19(1):85-95
pubmed: 23185040
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cell Cycle. 2010 Mar 15;9(6):1194-206
pubmed: 20237414
World J Stem Cells. 2015 Jan 26;7(1):137-48
pubmed: 25621113
Cancer Res. 2013 Feb 1;73(3):1219-31
pubmed: 23269272
Biosci Rep. 2019 Apr 12;39(4):
pubmed: 30886064
Target Oncol. 2017 Aug;12(4):387-399
pubmed: 28664387
Am J Surg Pathol. 2013 Sep;37(9):1311-8
pubmed: 24076771
Semin Cancer Biol. 2021 Jan;68:230-241
pubmed: 32113999
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194401
Acta Pharm Sin B. 2021 Jan;11(1):55-70
pubmed: 33532180
Biochim Biophys Acta. 2014 Dec;1840(12):3494-3502
pubmed: 25240776
BMC Cancer. 2018 Apr 2;18(1):357
pubmed: 29609538
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Cancer Res. 2016 Jun 1;76(11):3224-35
pubmed: 27197203
Neoplasia. 2012 Jun;14(6):519-25
pubmed: 22787433
BMB Rep. 2017 Mar;50(3):117-125
pubmed: 27998397
Front Oncol. 2019 Oct 24;9:1104
pubmed: 31709180
Cancers (Basel). 2021 Jan 20;13(3):
pubmed: 33498502
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5
pubmed: 19666588
BMC Infect Dis. 2021 May 5;21(1):422
pubmed: 33952203
Biomed Pharmacother. 2018 Jan;97:1445-1453
pubmed: 29156535
Front Oncol. 2019 Jul 10;9:626
pubmed: 31355143
Cancer Res. 2014 Jul 1;74(13):3579-90
pubmed: 24812274
J Biomed Sci. 2018 Mar 06;25(1):20
pubmed: 29506506
Oncotarget. 2013 Dec;4(12):2462-75
pubmed: 24318570
Cancer Sci. 2017 Jul;108(7):1357-1367
pubmed: 28421697
Cell. 2015 Feb 26;160(5):963-976
pubmed: 25723170
Adv Cancer Res. 2016;131:159-91
pubmed: 27451127
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781344
Oncol Rep. 2009 Nov;22(5):1129-34
pubmed: 19787230
J Transl Med. 2020 Feb 3;18(1):52
pubmed: 32014047
BMC Cancer. 2015 Oct 24;15:785
pubmed: 26499463
Nat Rev Drug Discov. 2014 Jul;13(7):497-512
pubmed: 24981363
J Obstet Gynaecol Res. 2014 May;40(5):1389-98
pubmed: 24750491
Cancer Cell Int. 2014 Jan 13;14(1):3
pubmed: 24418020
Gynecol Oncol. 2008 Dec;111(3):438-43
pubmed: 18835493
Mod Pathol. 2014 Jun;27(6):887-98
pubmed: 24309324
Chin J Cancer. 2013 Nov;32(11):582-93
pubmed: 24206916
Eur J Pharm Biopharm. 2014 Nov;88(3):945-53
pubmed: 25128854
Biomaterials. 2012 Apr;33(10):2961-70
pubmed: 22245557
BMC Cancer. 2012 Jan 28;12:48
pubmed: 22284662
Med Hypotheses. 2012 Oct;79(4):430-2
pubmed: 22818853
Stem Cells. 2006 Mar;24(3):506-13
pubmed: 16239320
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33
pubmed: 15381773
Front Oncol. 2020 Mar 11;10:247
pubmed: 32219062
Oncotarget. 2015 Jun 30;6(18):16437-48
pubmed: 25999351
Nat Cell Biol. 2014 Jun;16(6):488-94
pubmed: 24875735
Drug Deliv. 2021 Dec;28(1):510-519
pubmed: 33657950
J Clin Med. 2019 Jun 26;8(7):
pubmed: 31247937
J Cell Biochem. 2019 Mar;120(3):3046-3055
pubmed: 30536969
Sci Rep. 2015 Sep 08;5:13744
pubmed: 26345302
Curr Pharm Des. 2014;20(5):793-807
pubmed: 23688078
Front Oncol. 2021 May 07;11:639339
pubmed: 34026616
Oncol Lett. 2013 Dec;6(6):1673-1680
pubmed: 24260061
Oncotarget. 2017 May 23;8(21):35351-35367
pubmed: 27343550
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Lab Invest. 2012 May;92(5):744-52
pubmed: 22349639
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
J Exp Clin Cancer Res. 2019 Jan 24;38(1):33
pubmed: 30678687
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Oncotarget. 2017 May 23;8(21):35326-35338
pubmed: 28186961
BMC Cancer. 2017 Aug 30;17(1):593
pubmed: 28854900
Int J Mol Sci. 2013 Dec 18;14(12):24706-25
pubmed: 24351843
Oncol Lett. 2019 Oct;18(4):3423-3432
pubmed: 31516560
BMC Cancer. 2017 Apr 27;17(1):292
pubmed: 28449663
Mol Biol Rep. 2014;41(4):1993-2004
pubmed: 24420854
Ann Surg Oncol. 2016 Jan;23(1):163-70
pubmed: 25916979
Mol Med Rep. 2014 Jun;9(6):2117-23
pubmed: 24676900
Oncotarget. 2015 Nov 24;6(37):39550-63
pubmed: 26474460
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455616
Cancer Lett. 2015 Jan 28;356(2 Pt B):321-31
pubmed: 25281477
Cell Prolif. 2015 Dec;48(6):611-25
pubmed: 26597379
Trends Genet. 2022 Apr;38(4):379-394
pubmed: 34728089
Oncol Lett. 2018 Nov;16(5):5525-5534
pubmed: 30344706
J Gynecol Oncol. 2014 Jul;25(3):249-59
pubmed: 25045438
Front Oncol. 2020 Mar 17;10:319
pubmed: 32257947
Nat Rev Cancer. 2012 Nov;12(11):767-75
pubmed: 23051844
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Cancer Prev. 2015 May;24(3):223-30
pubmed: 25714783
Front Med (Lausanne). 2021 Jul 28;8:682366
pubmed: 34395473
PLoS One. 2018 Oct 29;13(10):e0206685
pubmed: 30372483
Front Mol Biosci. 2020 Apr 30;7:79
pubmed: 32426371
Cancer Biol Ther. 2019;20(6):912-921
pubmed: 30829552
Drug Discov Today. 2014 Dec;19(12):1953-63
pubmed: 25256776
Clin Epigenetics. 2021 May 29;13(1):120
pubmed: 34051847
Gynecol Obstet Invest. 2015 Jun 20;:
pubmed: 26113008
Oncol Lett. 2017 Sep;14(3):3536-3544
pubmed: 28927110
Am J Cancer Res. 2018 Jul 01;8(7):1126-1141
pubmed: 30094089
Physiol Rev. 2019 Apr 1;99(2):1047-1078
pubmed: 30648461
Cancer Rep (Hoboken). 2019 Apr;2(2):e1144
pubmed: 32721115
Front Pharmacol. 2021 Apr 19;12:648407
pubmed: 33953682
Br J Cancer. 2010 Mar 2;102(5):789-95
pubmed: 20104230
J Thorac Dis. 2016 Nov;8(11):2971-2974
pubmed: 28066560
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030